Partner With Us

Illuminating biologics discovery with AI

Ailux Biologics partners with leading pharmaceutical and biotech companies to discover and develop best-in-class biologics. Dedicated AI solutions, every step of the way.


A new chapter for biologics discovery

Biologics discovery is a journey with different challenges at every turn. We tailor a specific set of AI engines and wet lab tools to each challenge, recognizing that the discovery process is as unique as its goals.


Fully validated proprietary AI engines and wet lab methods to target the industry’s most challenging bottle necks

Three synergistic AI engines

Lorem ipsum dolor sit amet consectetur. Malesuada orci eleifend pharetra dui sit eget vel.

Explore our technology
Protein complex structure prediction to unlock limitless applications
Generative AI to explore extremely large sequence space
Predictive AI to evaluate and select best candidates

Value-added applications to deliver highly differentiated biologics

How we deliver value
Three synergistic AI - Hard targets

Hard targets

Three synergistic AI - Next-gen engineering

Next-gen engineering

Three synergistic AI - Raise the bar

Raise the bar

for conventional campaigns


Ailux collaborates with partners to tackle challenging targets and elevate lead candidates to the next stage of development

Partner with us
news & events

Explore our upcoming news & events

Together, let’s push the boundaries of medicine

The future of biotechnology is collaborative. We believe the best solutions come from working together with companies and researchers who share our vision. Are you ready to push the boundaries of what’s possible?

Case Study

Tapping into a greater search space for more quality hits using AI.

Immune Repertoire Analysis

In silico screening of millions of antibody sequences in the immune repertoire 

VL Clonotypes
VH Clonotypes
NCS Datasets
Unique VL Sequences
Unique VH Sequences
Results and Insights

XploreSeqTM Identifies Hits with High Accuracy

XploreSeqTM routinely sequences millions of BCRs and identifies hits with high confidence (see figure). In this project, XploreSeq predicted 717 binders, from which 48 were randomly chosen for expression and testing. 66.7% (32/48) were confirmed to be binders, and only 18.6% (6/32) binders overlap with hybridoma hits.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from - Youtube
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound